A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | MicrobiomeTrials

← Back to trials

NCT06935370

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-05-20Est. Completion: 2029-02-04

Enrollment target: 4,200 participants

Locations

Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States
Drug Research and Analysis Corporation, Montgomery, Alabama, United States
Cure Clinical Research, Beverly Hills, California, United States
Valley Clinical Trials, Inc., Covina, California, United States
North Coast Cardiology, Encinitas, California, United States
Orange County Research Center, Lake Forest, California, United States
Merced Vein and Vascular Center, Merced, California, United States
Radin Cardiovascular Medical Group, Newport Beach, California, United States
Amicis Research Center - Nordhoff, Northridge, California, United States
University of California San Diego, San Diego, California, United States
Paradigm Clinical Research - San Diego, San Diego, California, United States
Amicis Research Corporate, Santa Clarita, California, United States
Care Access Research, Thousand Oaks, California, United States
Bridgeport Hospital, Bridgeport, Connecticut, United States
Bay Area Cardiology, Brandon, Florida, United States

Other microbiome trials you might be interested in

The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitationRecruiting

Mitral Valve ProlapseMitral Regurgitation

Mitral regurgitation (MR) is the second most frequent valvular heart disease and the second most frequent indication for…

Milan, ItalyEst. completion Jun 1, 2029

NORM-HF Pivotal StudyRecruiting

Heart FailureNYHA Class III Heart FailureNYHA Class II Heart Failure

This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstra…

Tulsa, United StatesEst. completion Aug 2029

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.